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Abstract
Background: To identify the most appropriate cut-off points of fasting glycemia for the screening of diabetes
mellitus type 2 (DM2) with the comparison of the properties of capillary glycemia (CG) and venous blood plasma
glycemia (PG) in a population of Japanese origin from the community of Mombuca, Guatapará - SP, Brazil.
Methods: This was a population-based descriptive cross-sectional study conducted on a sample of 131 individuals
of both genders aged 20 years or more (66.8% of the target population). CG was measured with a glucometer in a
blood sample obtained from the fingertip and PG was determined by an enzymatic method (hexokinase) in
venous blood plasma, after a 10-14 hour fast in both cases. Data were analyzed by the receiver operating
characteristic (ROC) curve in order to identify the best cut-off point for fasting glycemia (CG and PG) for the
diagnosis of DM, using the 2-hour plasma glycemia > 200 mg/dl as gold - standard.
Results: The ROC curve revealed that the best cut-off point for the screening of DM was 110 mg/dl for CG and
105 mg/dl for PG, values that would optimize the relation between individuals with positive and false-positive
results. The area under the ROC curve was 0.814 for CG (p < 0.01) and 0.836 for PG (p < 0.01).
Conclusions: The cut-off points of 105 mg/dl(5.8 mmol/l) for PG and of 110 mg/dl(6.1 mmol/l) for CG appear to
be the most appropriate for the screening of DM2 in the population under study, with emphasis on the fact that
the value recommended for CG is 5 mg/dl higher than that for PG, in contrast to WHO recommendations.
Background
Diabetes mellitus type 2 (DM2) is a highly prevalent dis-
ease of epidemic projection for the next few years both
in developed and developing countries [1], representing
an important public health problem in view of the high
morbidity and mortality of the disease itself and the
high costs involved in its control and in the treatment
of its complications. DM2 is among the 10 major causes
of death in several industrialized and emergent countries
[2,3]. In 2002, the cost of treating diabetic patients in
the US was more than double the cost of treating non-
diabetic individuals, amounting to approximately US
$132 billion [4].
Over the last few years, a worldwide trend has been
observed showing that migrant populations present a
pattern of morbidity-mortality that differs from that of
the community of origin of their parents, but follows
the disease profile of local residents. Epidemiological
s t u d i e sh a v ed e m o n s t r a t e dc h a n g e si nt h ep r e v a l e n c eo f
non-transmissible chronic diseases, DM2 in particular,
among Japanese migrants and their descendants. In this
respect, higher prevalences of DM2 (16-20%) have been
observed among Japanese residing in the US than
among Japanese residing in Japan (4-5%) [5,6]. Similarly,
a high prevalence of DM2 [7,8] (36.2%) and of impaired
glucose tolerance (IGT = 23.4%) have been detected
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ing to higher values than those detected in the Brazilian
population [9]. These changes are explained by modifi-
cations of life style, with the incorporation of new cul-
tural patterns and changes in eating habits. However,
other factors also participate in this process, such as
greater population longevity, miscegenation and the
sociodemographic transformation due to urbanization
and economic development [10].
Despite the proven benefit of early detection of the
disease [11], universal screening for DM2 has been
questioned [12]. The most accepted recommendation is
the screening of asymptomatic individuals with a greater
risk for the disease [13-15], using the determination of
fasting plasma glucose level as the worldwide accepted
method for screening and diagnosis. On the other hand,
in view of its practical application, agility, rapidity and
safety, the capillary glycemia (CG) test is an important
option for the screening of DM in detection campaigns
or in population studies [16].
The objective of the present population-based study
was to identify the best cut-off points of fasting glycemia
for the screening of DM2 and to compare the properties
of fasting capillary glycemia (CG) and fasting venous
plasma glycemia (PG) by the analysis of the areas under
the receiver operating characteristic (ROC) curve [17] in
a population of Japanese origin living in the community
of Mombuca, Guatapará - SP, Brazil.
Methods
The data were obtained in a cross-sectional descriptive
study conducted on the Japanese-Brazilian population of
Mombuca, Guatapará - SP, during the period from
April to December 2005. Among 1
st and 2
nd generation
individuals (Issei and Nissei, respectively) of both gen-
ders and older than 20 years, 131 (66.8% of the popula-
tion in this age range) agreed to participate in the study.
The study was approved by the Research Ethics Com-
mittee of the Health Teaching Center of the Faculty of
Medicine of Ribeirão Preto-USP, under protocol n° 104/
03 and all subjects gave written informed consent to
participate.
On a scheduled date, each participant came to the
office of the Agricultural and Sports Association of Gua-
tapará for information about the study. After a fasting
period of 10 to 14 hours, a venous blood sample was
obtained from each subject for PG determination and a
blood sample was obtained from a fingertip for the
determination of CG. The blood samples were collected
into vacuum tubes containing sodium fluoride and used
for PG determination by enzymatic method (hexokinase)
with a Cobas Mira Plus Analyser. CG was measured
with a glucometer (Advantage-Roche) and reported as
whole blood glucose level. Individuals presenting CG of
less than 200 mg/dl were then asked to perform the 75
g glucose tolerance test, excluding those with previously
diagnosed diabetes.
Subjects were considered to have diabetes mellitus
when their fasting glycemia was ≥ 126 mg/dl(7.0 mmol/
l) or when their glycemia was ≥ 200 mg/dl(11.1 mmol/l)
2 hours after 75 g glucose load, or if they were under
treatment for diabetes. Subjects were considered to be
pre-diabetic when their fasting glycemia was 110(6.1
mmol/l) to 126 mg/dl (impaired fasting glycemia) and/
or when their glycemia was 140(7.8 mmol/l) to 200 mg/
dl 2 hours after glucose overload (impaired glucose tol-
erance). This diagnostic criteria for diabetes or pre-dia-
betes was based on plasma glucose levels [16].
Statistical Analysis
C Ga n dP Gd a t aw e r ec o m p a r e db e t w e e nt h ed i a b e t i c
and non-diabetic groups by the Student t-test for inde-
pendent samples, with the level of significance set at p <
0.05. CG and PG were compared in terms of sensitivity
and specificity using the ROC curve, considering the
diagnostic standard for diabetes mellitus to be PG ≥ 200
mg/dl(11.1 mmol/l) 2 hours after the ingestion of 75 g
anhydrous glucose. The criterion used to select the cut-
off points of the fasting glycemias (CG and PG) was
based on the values with the closest sensitivity and spe-
cificity. The areas under the ROC curve for fasting PG
and CG were compared by the nonparametric test pro-
posed by DeLong et al. [18]. For interpretation of the
results, it is considered that the greater the area under
the ROC curve, the greater the discriminant power of
the test for a determined outcome.
Results
The clinical data of the participants are presented on
Table 1. Among the 131 individuals evaluated, five were
excluded because they were previously diagnosed diabetics
and nine did not perform the CG test. Among the subjects
without DM, mean CG was significantly higher (8%) than
PG, whereas among subjects with DM the differences
were nonsignificant, although mean CG was 5% higher
than PG (Table 2). The prevalence of DM and IGT in this
group were 13.7% and 14.5%, respectively, and the fre-
quency of hypertension (>140/90 mmHg) was 48.1%.
Table 1 Clinical data of the Japanese-Brazilian population
of Mombuca, Guatapará-SP, 2005 (Mean ± SD).
Total
(N = 131)
Men
(N = 54)
Women
(N = 77)
Age (years) 56.7 ± 15.9 55.1 ± 15.9 57.8 ± 16.1
Body Weight (Kg) 61.7 ± 14.3 70.6 ± 14.5 55.2 ± 10.2
Height (m) 1.6 ± 0.1 1.7 ± 0.1 1.5 ± 0.1
BMI (kg/m
2) 24.7 ± 4.0 25.4 ± 4.2 24.1 ± 3.9
Waist Circumference (cm) 84.9 ± 10.6 88.6 ± 10.1 83.1 ± 10.7
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for DM screening was 105 mg/dl for PG and 110 mg/dl
for CG (Fig. 1), values that would optimize the relation
between subjects with positive and false-positive results.
The level of 110 mg/dL in CG showed 77.8% sensitivity
and 82.% specificity and the level of 105 mg/dL in PG
showed 72.7% sensitivity and 93.0% specificity. It can be
seen that PG showed a better power for the detection of
DM, with a greater area under the ROC curve (0.836 -
p < 0.01) compared to CG (0.814 - p < 0.01), although
the difference was nonsignificant (p = 0.66).
Discussion
The high prevalence of DM and the epidemic projec-
tions of the disease for the next few years in both devel-
oped and developing countries are a source of concern
for the health area authorities. In addition, the fact that
35 to 50% of the individuals with DM do not know that
they have the disease and that at the time of diagnosis
the patients already present micro- and macrovascular
complications, supports the importance of establishing
an early diagnosis of DM, which would prevent the
occurrence of many of these complications [19,20].
The comparison of glycemia values obtained from
capillary blood and from venous plasma blood is a sub-
ject of extensive discussion [21-25]. However, it is
known that the level of glucose in blood after a few
hours of fasting varies according to the method
employed for determination and the material used, i.e.,
capillary blood, venous blood, and serum/plasma or
whole blood [26].
In a study on the validation of CG versus PG for the
detection of DM and IGT, Kruijshoop et al. [22]
detected a strong correlation between the two para-
meters both in the fasting condition (r = 0.92) and in
the postprandial condition (r = 0.82), thus demonstrat-
ing the validity of the use of CG in the screening
phase of epidemiological studies. In agreement with
our results, the CG values detected by Kruijshoop et
al. [22] were higher than PG values both for diabetic
and normoglycemic or IGT subjects in the fasting
condition.
Table 2 Fasting CG and PG levels of the Japanese-Brazilian population of Mombuca, Guatapará-SP, 2005 (Mean ± SD).
GLYCEMIA Normoglycemic + IGT DM p-value*
CG (mg/dl) (N = 117) 95.9 ± 15.8 120.5 ± 19.1 < 0.0001
PG (mg/dl) (N = 126) 88.4 ± 8.9 113.8 ± 20.1 < 0.0001
p-value* < 0.0001 0.4140
* Student t-test
Figure 1 ROC curve for fasting PG (A) and CG (B) for the identification of DM in the Japanese-Brazilian population of Mombuca,
Guatapará-SP, 2005.
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higher result compared to methods that use whole
venous blood, which in turn yield about 5% lower glyce-
mia results compared to capillary blood [14,26]. How-
ever, according to the WHO [16], under fasting
conditions, plasma venous glycemia values are about
10% higher than CG values.
Analysis of the sensitivity and specificity of diagnostic
tests by constructing the ROC curve has been recom-
mended in epidemiological studies. In the present study,
the cut-off points with the best specificity and sensitivity
for CG and PG obtained on the basis of the ROC curve
were 110 mg/dl and 105 mg/dl, respectively. The areas
under the curve for CG and PG were quite close, 0.814
and 0.836, respectively, showing the expressive capacity
of the tests in detecting DM. However, when the areas
are superimposed, a separation of the 105 and 110 mg/
dl points is noted, suggesting that, even though the lit-
erature shows that PG values are higher than CG values,
regarding the population studied here, PG values of 105
mg/dl and CG values of 110 mg/dl should be used.
It is important to point out a limitation of this study
for the proposed objectives by the number of partici-
pants, but the use of CG showed useful for decision tak-
ing immediately, i.e., to perform or not a 75 g glucose
OGTT.
Conclusions
In conclusion, our data indicate that the cut-off points
of 105 mg/dl(5.8 mmol/l) and 110 mg/dl(6.1 mmol/l)
for PG and CG, respectively, are highly sensitive and
specific for the diagnosis of DM2 and therefore would
be appropriate for the screening of DM2 in this study
population. It is important to give emphasis to the fact
that the value recommended for CG is 5 mg/dl higher
than that for PG, in contrast to WHO
recommendations.
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